SCHEDULE 13D/A Filed 2026-11-03 Event 2026-10-30 SEC 0001193125-26-445875 →

LIGAND PHARMACEUTICALS INC → Pelthos Therapeutics Inc. PTHS

Stake: — Shares: 5,189,177.1 Class: Common Stock, par value $0.0001 per share

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 23/100

Active Schedule 13D filer baseline
Short interest building (+36.0% vs prior settlement)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

8 transactions

0 buys · 8 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-10-15

DTC 2.99

142,250 shares short · +36.0% vs prior

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-04-02	Friedberg Ezra M	director	Sale	293	$20.51	$6K
2026-04-02	Friedberg Ezra M	director	Sale	265	$21.36	$6K
2026-04-02	Greenleaf Peter	director	Sale	420	$20.52	$9K
2026-04-02	Greenleaf Peter	director	Sale	377	$21.36	$8K
2026-04-02	Malamut Richard	director	Sale	310	$20.51	$6K
2026-04-02	Malamut Richard	director	Sale	280	$21.36	$6K
2026-04-02	Pauls Matthew	director	Sale	415	$20.52	$9K
2026-04-02	Pauls Matthew	director	Sale	371	$21.36	$8K

Other Filings by LIGAND PHARMACEUTICALS INC

Filed	Form	Issuer	Stake	Shares
2026-05-01	SCHEDULE 13D	XOMA ROYALTY CORPORATION XOMAP	47.00%	8,062,678	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →